Regeneron
Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source. This covers Regeneron Pharmaceuticals as a whole, including the Regeneron Genetics Center. Lab automation in Preclinical Manufacturing and Process Development counts as process development and sits outside the research labs and data theme.
Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.
Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.
Scores
| Theme | Priority (1 to 10) | Delivery (0 to 10) | Stage | Commitments made public, last 12 months | R&D roles open on 6 Oct 2026 |
|---|---|---|---|---|---|
| AI in drug discovery | 7 | 4 | live | 0 | 3 |
| Research labs and data | 8 | 4 | live | 0 | 4 |
The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.
Summary
Regeneron scores 7 out of 10 for priority on AI in drug discovery and 8 out of 10 on research labs and data, both tied to its 2030 goal to sequence 10 million samples and integrate AI and big data tools into drug discovery. Both themes are shown live with a delivery score of 4 out of 10: the Regeneron Genetics Center uses lab automation and cloud computing, has sequenced more than 3 million samples and has identified more than 40 new genetic targets. No new commitment in either theme was identified in the last 12 months or the year before. On 6 October 2026 Regeneron had 3 open R&D roles tied to AI in drug discovery and 4 tied to research labs and data, including a scientific data product owner and a research solutions director. An R&D developer posting names Sapio, Benchling and Dotmatics as the lab platforms the role works on, and other postings ask for Databricks and Claude experience.
AI in drug discovery
What the company says: Priority 7
We aim to complete sequencing of 10 million samples and integrate AI and big data tools to improve drug discovery and digital health solutions by 2030.
2025 Responsibility Report, 28 Apr 2026, p. 17
through the Regeneron Genetics Center ... we’re committing to sequencing 10 million samples and integrating artificial intelligence (AI) and big data tools to advance drug discovery
Responsibility at Regeneron: A Look Back and a Look Ahead (story), 28 Apr 2026
SCIENCE-LED 2030 GOALS WILL HOLD US ACCOUNTABLE ... Completing sequencing of 10M samples and integrating AI and big data tools to improve drug discovery
Regeneron Corporate Presentation, July 2026, Jul 2026, p. 31
While artificial intelligence ("AI") offers enormous potential, it depends on large, high-quality datasets, and integrating those data with AI is already accelerating our drug discovery and development efforts.
2026 Proxy Statement (DEF 14A), 24 Apr 2026
Regeneron Genetics Center LLC (RGC®), a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc., leverages de-identified clinical, genomic, proteomic, and other types of molecular data
Regeneron 2025 Annual Report incl. Form 10-K FY2025, 4 Feb 2026, p. 22
What it shows running: Delivery 4, live
We use innovative technologies, such as machine learning, to sequence exomes, align with health information and perform large-scale analyses to make meaningful associations between genes and diseases.
Our lab technicians, data scientists and bioinformaticians collect and analyze large amounts of data using cloud technology to simultaneously look at genes, proteins, health records and more.
The Regeneron Scientific Journey (story), 9 Jun 2026
RGC leverages organoid models, siRNA, and CRISPR knockout models to validate genetic associations that lead to new therapeutic targets. ... These efforts at RGC have led to the identification of more than 40 novel genetic targets.
Regeneron 2025 Annual Report incl. Form 10-K FY2025, 4 Feb 2026, p. 22
Additional genetic-defined targets discovered by Regeneron Genetics Center, each with pipeline-in-a-product potential, expected to enter clinic in 2026-2027
Regeneron Corporate Presentation, January 2026, Jan 2026, p. 14
which is large-scale ... human genetics, which allows us to use AI in ways that other people can't. And that allows us to pick targets.
Q4 2025 earnings call transcript (30 Jan 2026), 30 Jan 2026, p. 13
integrating those data with AI is already accelerating our drug discovery and development efforts
2026 Proxy Statement (DEF 14A), 24 Apr 2026
Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Commitments made public in the year before: 0
None identified in the reviewed sources.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 3
- Associate Director, Translational PK/PD Modeling, TARRYTOWN
- Associate Manager, Statistical Genetics (Applied Bioinformatics Scientist), TARRYTOWN
- Principal Scientist, Translational PK/PD Modeling, TARRYTOWN
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Technology named in these postings
Asked for as experience: Claude.
A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.
Research labs and data
What the company says: Priority 8
Integrating Genetics, Proteomics, and Big Data ... World’s largest DNA and proteomics-linked healthcare database, enabling advanced drug discovery, development, and healthcare analytics
Regeneron Corporate Presentation, January 2026, Jan 2026, p. 3
Integrating Genetics, Proteomics, and Big Data ... World's largest DNA and proteomics-linked healthcare database, enabling advanced drug discovery, development, and healthcare analytics
Regeneron Corporate Presentation, July 2026, Jul 2026, p. 3
over the last decade, we have made enormous investments to build the world's largest collection of "big data" in which de-identified electronic health records ("EHRs") are linked to molecular data (DNA sequence and proteomics data).
2026 Proxy Statement (DEF 14A), 24 Apr 2026
We intend to continue building RGC's world-class proteogenomics data resources ... We aim to complete sequencing of 10 million samples ... by 2030.
2025 Responsibility Report, 28 Apr 2026, p. 17
Our aim is to sequence at least one million non-European ancestry samples by the end of 2027.
2025 Responsibility Report, 28 Apr 2026, p. 16
As part of the collaboration, Regeneron will invest up to $200 million in TriNetX.
This collaboration will enable expansion of Regeneron's world-leading genomic and proteomic Electronic Health Record (EHR)-linked database, a key driver of the company's industry-leading therapeutics pipeline.
Regeneron Genetics Center LLC (RGC®), a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc., leverages de-identified clinical, genomic, proteomic, and other types of molecular data
Regeneron 2025 Annual Report incl. Form 10-K FY2025, 4 Feb 2026, p. 22
Senior Vice President, Head of RGC and Co-head of Regeneron Genetic Medicines
What it shows running: Delivery 4, live
RGC utilizes laboratory automation and innovative approaches to cloud computing to achieve high-quality throughput, attaining over 3 million samples sequenced to date.
Regeneron 2025 Annual Report incl. Form 10-K FY2025, 4 Feb 2026, p. 22
we partnered with DNAnexus to provide infrastructure ... today, it underpins everything from large-scale sequencing projects to trusted research environments used by global collaborations
Strategic Investments for a Stronger RGC Future (story), 13 Jan 2026
We are also introducing more automation to improve coverage uniformity, and re-engineer bioinformatics workflows so sequencing data can be analyzed even faster.
Strategic Investments for a Stronger RGC Future (story), 13 Jan 2026
Together, we built the systems required for modern genomics and established environments that allow over 150 collaborators to work with us securely and at speed.
Strategic investments for a stronger RGC future (story), 13 Jan 2026
By rethinking flow cell design, chemistry and machine learning, the new platform has already reduced costs by tens of millions of dollars
Strategic Investments for a Stronger RGC Future (story), 13 Jan 2026
Improving the efficiency of managing and analyzing large volumes of data ... Leveraging real-time automated data acquisition and visualization as well as instrument automation in our development work, reducing
2025 Responsibility Report, 28 Apr 2026, p. 49
Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Commitments made public in the year before: 0
None identified in the reviewed sources.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 4
- Senior Developer - Research and Development, TARRYTOWN
- Associate Director Solutions Partner (Scientific Data Product Owner), TARRYTOWN
- Associate Manager Next-Generation Sequencing (NGS) Data Analysis, TARRYTOWN
- Senior Director - Research Solutions, Hyderabad
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Technology named in these postings
Named as in use: Sapio, Benchling, Dotmatics.
Asked for as experience: Databricks.
A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.
Two questions to investigate (Ortent's interpretation)
- LIMS, ELN, lab automation and scientific data work sits in several units: an R&D developer team, a scientific data product owner for the enterprise data lake, the Regeneron Genetics Center's genome informatics group and a research technology centre in India. Who decides on platform selection, and how do these units work together?
- AI for discovery appears in Research, in the Regeneron Genetics Center and in the 2030 goal, while an Enterprise Data and AI organisation under a Chief AI Officer runs AI governance, including use-case intake. Who holds decision rights over discovery AI tools, does a purchase go through that intake, and how is the 2030 goal funded when no budget is stated?
Coverage limits
Business Wire blocked access, GlobeNewswire was unreachable and PR Newswire search returned results only from about October 2025, so partner releases from the year before are thinly covered. The Regeneron newsroom and investor sites blocked access at times, careers.regeneron.com blocked access throughout, and four AI postings seen only on the careers site were not recorded. No 10-K was read from SEC EDGAR, and several planned searches, including vendor searches for LIMS, ELN and lab automation deals, were not run for lack of search budget. Zero commitments here is a search result, not proof that Regeneron made none.
Clarity when it counts.
For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.
Request a 30-minute intro call